A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma (TRIlogy-2)
A Phase 1b Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for ramantamig treatment regimens and JNJ-102299639 treatment regimens; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of ramantamig and JNJ-102299639 treatment regimens at selected RP2D(s).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Amsterdam, 네덜란드, 1081 HV
- 모병
- VU Medisch Centrum
-
Groningen, 네덜란드, 9713 GZ
- 모병
- Universitair Medisch Centrum Groningen
-
Utrecht, 네덜란드, 3584 CX
- 모병
- UMC Utrecht
-
-
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- 모병
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Winship Cancer Institute Emory University
-
-
-
-
-
Barcelona, 스페인, 08036
- 모병
- Hosp. Clinic de Barcelona
-
Salamanca, 스페인, 37007
- 모병
- Hosp Clinico Univ de Salamanca
-
-
-
-
-
Haifa, 이스라엘, 3436212
- 모병
- Carmel Medical Center
-
Ramat Gan, 이스라엘, 52621
- 모병
- Sheba Medical Center
-
Tel Aviv, 이스라엘, 64239
- 모병
- Tel Aviv Sourasky Medical Center
-
Yeruham, 이스라엘, 9112001
- 모병
- Hadassah Medical Center
-
-
-
-
-
Clayton, 호주, 3168
- 모병
- Monash Medical Centre
-
Fitzroy, 호주, 3065
- 모병
- St Vincents Hospital Melbourne
-
Melbourne, 호주, 3000
- 모병
- Peter MacCallum Cancer Centre
-
Waratah, 호주, 2298
- 모병
- Calvary Mater Newcastle Hospital
-
Wollongong, 호주, 2500
- 모병
- Wollongong Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (R/R MM):
- Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
- Meet treatment regimen-specific requirements as follows: Treatment regimen A (ramantamig+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (ramantamig+pomalidomide): Have received greater than or equal to (>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR >=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, E and H: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments
- Have a weight >=40 kilograms
- Must have an Eastern Cooperative Oncology Group status of 0 or 2
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level >= 0.5 gram per deciliter (g/dL); or b) Urine M-protein level >=200 milligram (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated
Inclusion criteria for newly diagnosed amyloid light chain (ND AL) Amyloidosis
- Have a histopathological diagnosis of amyloidosis
- Have an ECOG performance status of 0 to 1
Inclusion criteria for High-risk smoldering multiple myeloma (SMM)
- Have a diagnosis of SMM (per IMWG criteria) for less than or equal to (<=) 5 years with measurable disease at the time of enrollment as defined in the protocol
- Have an ECOG performance status of 0 to 1
Exclusion Criteria for NDMM and R/R MM:
- Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days
- Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant <=12 weeks before the first dose of study treatment
- Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy grade <=3)
- Prior treatment with CD3-redirecting therapy
Exclusion Criteria for ND AL Amyloidosis
- Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60 percent (%) plasma cells in the bone marrow, or hypercalcemia
- Macroglossia that impairs swallowing difficulty
- Prior therapy for AL amyloidosis or multiple myeloma
Exclusion Criteria for High-risk SMM
- Multiple myeloma, requiring treatment
- Primary systemic AL (immunoglobulin light chain) amyloidosis
Exclusion criteria for all participants:
- Any serious underlying medical conditions, such as: Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment; active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment; cardiovascular dysfunction; pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation; human immunodeficiency (HIV) infection; active hepatitis B or C infection; stroke or seizure within 6 months prior to first dose of study treatment
- Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than (<) 50 percent (%)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Treatment Regimen A and C: Ramantamig+Daratumumab
Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive ramantamig along with daratumumab to establish the recommended phase 2 doses (RP2D[s]) of the ramantamig during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
실험적: Treatment Regimen B: Ramantamig+Pomalidomide
Participants who have received greater than or equal to (>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or >=2 prior lines of therapy, including a PI and lenalidomide will receive ramantamig along with pomalidomide to establish the RP2D(s) of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Pomalidomide will be administered orally. Ramantamig will be administered subcutaneously. |
|
실험적: Treatment Regimen D and E: Ramantamig + Daratumumab + Lenalidomide Combination
Participants with NDMM will receive ramantamig along with daratumumab and lenalidomide to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Lenalidomide will be administered orally. Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
실험적: Treatment Regimen F: Ramantamig+ Daratumumab
Participants with newly diagnosed amyloid light chain (ND AL) amyloidosis will receive ramantamig in treatment regimen F along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
실험적: Treatment Regimen G: Ramantamig + Daratumumab
Participants with high-risk smoldering multiple myeloma (SMM) will receive ramantamig in treatment regimen G along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. Ramantamig will be administered subcutaneously. |
|
실험적: Treatment Regimen H: JNJ-102299639
Participants with NDMM in treatment regimen H will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
|
실험적: Treatment Regimen I: JNJ-102299639
Participants with ND AL Amyloidosis in treatment regimen I will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
|
실험적: Treatment Regimen J: JNJ-102299639
Participants with high-risk SMM in treatment regimen J will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens. |
JNJ-102299639 will be administered subcutaneously. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
기간: Up to 28 days
|
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 28 days
|
|
Number of Participants with Adverse Events (AEs) by Severity
기간: Up to 3 Years and 3 months
|
An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event. |
Up to 3 Years and 3 months
|
|
Number of Participants with Clinically Significant Laboratory Abnormalities
기간: Up to 3 Years and 3 months
|
Participants with clinically significant laboratory abnormalities (hematology and chemistry) will be reported. |
Up to 3 Years and 3 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Overall Response Rate
기간: Up to 3 Years and 3 months
|
Overall response rate is defined as percentage of participants with newly diagnosed multiple myeloma (NDMM), relapsed or refractory multiple myeloma (R/R MM), or high-risk smoldering multiple myeloma (SMM) who have a partial response (PR) or better evaluated by the investigator as per international myeloma working group (IMWG) 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response Rate
기간: Up to 3 Years and 3 months
|
VGPR or better response rate is defined as the percentage of participants with NDMM, R/R MM, or high-risk SMM who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With CR or Better Response Rate
기간: Up to 3 Years and 3 months
|
CR or better response rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With sCR or Better Response Rate
기간: Up to 3 Years and 3 months
|
sCR rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve an sCR according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Duration of Response (DOR)
기간: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per IMWG 2016 response criteria, or death due to progression, whichever occurs first in participants with NDMM, R/R MM, or high-risk SMM. |
Up to 3 Years and 3 months
|
|
Time to Response (TTR)
기간: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participants with NDMM, R/R MM, or high-risk SMM has met all criteria for PR or better as defined by IMWG 2016 response criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Hematologic Response As Defined by International Amyloidosis Consensus Criteria
기간: Up to 3 Years and 3 months
|
Hematologic response is defined as percentage of participants with newly diagnosed amyloid light chain (ND AL) amyloidosis who achieve complete response, very good partial response, partial response, no response and progression as defined by International amyloidosis consensus criteria present in the protocol will be reported. |
Up to 3 Years and 3 months
|
|
DOR as Defined by International Amyloidosis Consensus Criteria
기간: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per International amyloidosis consensus criteria, or death due to progression, whichever occurs first in participants with ND AL amyloidosis. |
Up to 3 Years and 3 months
|
|
TTR as Defined by International Amyloidosis Consensus Criteria
기간: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant with ND AL amyloidosis has met all criteria for PR or better as defined by International amyloidosis consensus criteria. |
Up to 3 Years and 3 months
|
|
Serum Concentration of Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
Serum samples will be analyzed to determine concentrations of ramantamig, daratumumab, and JNJ-102299639. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUCinf) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
AUCinf for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to the Last Measurable Concentration [AUC(0-t)] for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
AUC(0-t) for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve During the Dosing Interval (AUCtau) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
AUCtau for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Maximum Serum Concentration (Cmax) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
Cmax for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Half Life (T1/2) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
T1/2 for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Time to Reach Cmax (Tmax) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
Tmax for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Systemic Clearance (CL/F) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
CL/F for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Apparent Volume of Distribution at Steady State (Vss/F) for Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
Vss/F for ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies to Ramantamig, Daratumumab, and JNJ-102299639
기간: Up to 3 Years and 3 months
|
Participants with anti-drug antibodies to ramantamig, daratumumab, and JNJ-102299639 will be reported. |
Up to 3 Years and 3 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈관 질환
- 심혈관 질환
- 신생물
- 대사 질환
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프 증식 장애
- 면역증식성 장애
- 전암 상태
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 단백질 결핍증
- 고감마글로불린혈증
- 아밀로이드증
- 영양 및 대사 질환
- 헴 및 림프병
- 면역글로불린 경쇄 아밀로이드증
- 연기가 나는 다발성 골수종
- 다발성 골수종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 카르 복실 산
- 파이퍼 리딘
- 프탈리 미드
- 프탈산
- 산, 카르 보 사이 클릭
- 파이퍼리돈
- Isoindoles
- 레날리도마이드
- Pomalidomide
- 다라 토무 맙
기타 연구 ID 번호
기타 연구 ID 번호
- 79635322MMY1002
- 2024-515316-44-00 (레지스트리 식별자: EUCT number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .